Genomtec SA

As of March 31, 2026, Genomtec SA carries a market capitalization of 70.28M, placing it among publicly traded companies globally. Its enterprise value stands at 69.53M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Genomtec SA has 15.06M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Genomtec SA maintains a current ratio of 1.77, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Genomtec SA recorded an income tax benefit of -17,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 22, 2026, Genomtec SA's stock has declined approximately 53.40% over the past 52 weeks. The 50-day moving average sits at 3.42, while the 200-day moving average is 4.45.

These figures cover the twelve months ended March 31, 2026.

As of March 31, 2026, Genomtec SA holds 2.61M in cash and equivalents against 1.86M in total debt, resulting in a net debt position of -2.16M. Total book value stands at 7.02M, with working capital of 3.23M providing operational flexibility.